Last reviewed · How we verify

Encube Ethicals Pvt. Ltd. — Portfolio Competitive Intelligence Brief

Encube Ethicals Pvt. Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Elimite™ Cream (permethrin) 5% Elimite™ Cream (permethrin) 5% phase 3 Pyrethroid insecticide Voltage-gated sodium channels Dermatology / Parasitology
Solaraze 3% Topical Gel Solaraze 3% Topical Gel phase 3 retinoid retinoic acid receptors Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Fougera Pharmaceuticals Inc. · 1 shared drug class
  3. Galderma R&D · 1 shared drug class
  4. Infectopharm Arzneimittel GmbH · 1 shared drug class
  5. Kowa Company, Ltd. · 1 shared drug class
  6. South Plains Oncology Consortium · 1 shared drug class
  7. Stiefel, a GSK Company · 1 shared drug class
  8. Teva Pharmaceuticals USA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Encube Ethicals Pvt. Ltd.:

Cite this brief

Drug Landscape (2026). Encube Ethicals Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/encube-ethicals-pvt-ltd. Accessed 2026-05-16.

Related